» Articles » PMID: 10070091

Coronary Vasodilator Effects of BNP: Mechanisms of Action in Coronary Conductance and Resistance Arteries

Overview
Journal Am J Physiol
Specialty Physiology
Date 1999 Mar 10
PMID 10070091
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Brain natriuretic peptide (BNP), a hormone secreted predominantly in ventricular myocytes, may influence coronary vascular tone. We studied the coronary vasodilatory response to BNP under physiological conditions and after preconstriction with endothelin-1 (ET-1) in anesthetized pigs. Average peak-flow velocity (APV) was measured using intracoronary Doppler, and cross-sectional area (CSA) was measured using intravascular ultrasound. Coronary blood flow (CBF) was calculated. Intracoronary BNP induced dose-dependent increases in CSA, APV, and CBF similar in magnitude to those induced by nitroglycerin (NTG). The magnitude of BNP-induced vasodilation was accentuated after preconstriction with ET-1. Pretreatment with either the nitric oxide synthase inhibitor Nomega-nitro-L-arginine methyl ester or the cyclooxygenase inhibitor indomethacin attenuated the coronary vasodilator effect of BNP in resistance arteries without influencing epicardial vasodilation. Pretreatment with the ATP-sensitive potassium-channel blocker glibenclamide enhanced epicardial vasodilation in response to BNP. We conclude that BNP exerts coronary vasodilator effects, predominantly in epicardial conductance vessels. An accentuated vasodilatory response to BNP occurs in ET-1-preconstricted arteries. BNP-induced vasodilation in coronary resistance arteries may be partially mediated via nitric oxide and/or prostaglandin release.

Citing Articles

The clinical effect of recombinant human brain natriuretic peptide on asymptomatic peri-procedural myocardial injury after percutaneous transluminal coronary angioplasty.

Liang L, Tang R, Xie Q, Han J, Li W Sci Rep. 2020; 10(1):15902.

PMID: 32985551 PMC: 7522987. DOI: 10.1038/s41598-020-72710-3.


B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Holditch S, Schreiber C, Harris P, LaRusso N, Ramirez-Alvarado M, Cataliotti A Kidney Int. 2017; 92(3):657-668.

PMID: 28416225 PMC: 5557687. DOI: 10.1016/j.kint.2017.02.017.


Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials.

Gong B, Wu Z, Li Z BMJ Open. 2016; 6(1):e008545.

PMID: 26739721 PMC: 4716178. DOI: 10.1136/bmjopen-2015-008545.


Molecular and physiological effects of nesiritide.

Reichert S, Ignaszewski A Can J Cardiol. 2008; 24 Suppl B:15B-8B.

PMID: 18629383 PMC: 2794439. DOI: 10.1016/s0828-282x(08)71024-9.


Recent advances in natriuretic peptide research.

Woodard G, Rosado J J Cell Mol Med. 2008; 11(6):1263-71.

PMID: 18205700 PMC: 4401292. DOI: 10.1111/j.1582-4934.2007.00125.x.